Generic Yutrepia Availability
Last updated on Jul 9, 2025.
Yutrepia is a brand name of treprostinil, approved by the FDA in the following formulation(s):
YUTREPIA (treprostinil sodium - powder;inhalation)
-
Manufacturer: LIQUIDIA TECH
Approval date: May 23, 2025
Strength(s): EQ 0.0265MG BASE/INH [RLD], EQ 0.053MG BASE/INH [RLD], EQ 0.0795MG BASE/INH [RLD], EQ 0.106MG BASE/INH [RLD]
Is there a generic version of Yutrepia available?
No. There is currently no therapeutically equivalent version of Yutrepia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yutrepia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dry powder treprostinil for the treatment of pulmonary hypertension
Patent 10,898,494
Issued: January 26, 2021
Inventor(s): Roscigno; Robert Frank et al.
Assignee(s): LIQUIDIA TECHNOLOGIES, INC. (Morrisville, NC)A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Patent expiration dates:
- May 5, 2037✓
- May 5, 2037
-
Dry powder treprostinil for the treatment of pulmonary hypertension
Patent 11,660,304
Issued: May 30, 2023
Inventor(s): Roscigno; Robert Frank et al.
Assignee(s): LIQUIDIA TECHNOLOGIES, INC. (Morrisville, NC)A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Patent expiration dates:
- May 5, 2037✓
- May 5, 2037
-
Dry powder treprostinil for the treatment of pulmonary hypertension
Patent 11,712,442
Issued: August 1, 2023
Inventor(s): Roscigno; Robert Frank et al.
Assignee(s): LIQUIDIA TECHNOLOGIES, INC. (Morrisville, NC)A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Patent expiration dates:
- May 5, 2037✓
- May 5, 2037
-
Dry powder treprostinil for the treatment of pulmonary hypertension
Patent 11,744,835
Issued: September 5, 2023
Inventor(s): Roscigno; Robert Frank et al.
Assignee(s): Liquidia Technologies, Inc. (Morrisville, NC)A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Patent expiration dates:
- May 5, 2037✓
- May 5, 2037
-
Dry powder treprostinil for the treatment of pulmonary hypertension
Patent 11,744,836
Issued: September 5, 2023
Inventor(s): Roscigno; Robert Frank et al.
Assignee(s): Liquidia Technologies, Inc. (Morrisville, NC)A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Patent expiration dates:
- May 5, 2037✓
- May 5, 2037
More about Yutrepia (treprostinil)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: agents for pulmonary hypertension
- Breastfeeding
Patient resources
Other brands
Remodulin, Tyvaso, Orenitram, Tyvaso DPI
Professional resources
Other brands
Remodulin, Tyvaso, Orenitram, Tyvaso DPI
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.